CGTX
Cognition Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$114.37M
P/E Ratio
—
EPS
$-0.32
Beta
1.40
52W High
$3.83
52W Low
$0.22
50-Day MA
$1.05
200-Day MA
$1.39
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company is headquartered in Purchase, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-47.76M |
| Operating Margin | 0.00% |
| Return on Equity | -88.60% |
| Return on Assets | -76.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.39 |
| Price-to-Book | 3.34 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $89.35M |
| Float | $82.31M |
| % Insiders | 2.26% |
| % Institutions | 23.61% |
Historical Volatility
HV 10-Day
85.40%
HV 20-Day
118.70%
HV 30-Day
172.13%
HV 60-Day
129.78%
HV Rank
73.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($3.50 target)
4
BuyData last updated: 4/29/2026